Cencora
COR
$323.85
+0.78%
Cencora, Inc. is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail pharmacies, hospital networks, mail-order operators, and healthcare providers, while also operating commercialization services, global specialty logistics through World Courier, and animal health distribution via MWI Animal Health. Alongside McKesson and Cardinal Health, Cencora controls over 90% of the U.S. drug wholesale market, giving it a scale-driven, oligopolistic position reinforced by its 2021 acquisition of Europe's Alliance Healthcare, which broadened its international footprint. The current investor narrative centers on the strength of its specialty distribution businesses, which management credits for a raised fiscal 2026 EPS outlook, even as the stock has lagged the broader market over the past year amid concerns about thin distribution margins, drug pricing pressure, and the sustainability of recent earnings quality. With 12 analysts maintaining a consensus Buy rating and a $369.25 average target, the debate is whether Cencora's specialty-driven momentum and defensive cash flows can re-rate a stock that has underperformed the S&P 500 by roughly 15 percentage points over the trailing year.…
COR
Cencora
$323.85
Related headlines
Investment Opinion: Should I buy COR Today?
We assign a Hold rating on Cencora, balancing its defensive characteristics and attractive forward valuation against near-term earnings uncertainty and thin margins. The analyst consensus is Buy with an average target of $369.25, implying 19.5% upside, but the wide target range ($330–$430) and recent underperformance warrant caution. The core thesis is that Cencora's specialty distribution growth and strong free cash flow generation can drive a gradual re-rating, but the market needs clearer evidence of sustainable margin improvement.
The supporting evidence includes: 1) Revenue growth of 5.07% YoY in Q3 2026, driven by U.S. Healthcare Solutions; 2) Forward PE of 15.59x, which is reasonable for a defensive distributor and below the broader market; 3) Free cash flow of $4.06 billion TTM, funding dividends and buybacks; 4) PS ratio of 0.19x, a significant discount to its historical range of 0.42x–0.78x. These metrics suggest the stock is undervalued relative to its own history, but the PEG ratio of 7.05 indicates it is not cheap relative to growth.
The biggest risks that could invalidate the thesis are: 1) Continued margin compression below 4% gross margin, which would pressure earnings; 2) Failure to achieve the consensus EPS of $31.74, leading to multiple contraction; 3) A broader market downturn given the stock's high leverage. We would upgrade to Buy if gross margins stabilize above 4.5% and EPS growth accelerates, or downgrade to Sell if revenue growth falls below 3% or if free cash flow turns negative. Overall, the stock appears fairly valued to slightly undervalued, but lacks a near-term catalyst to drive significant outperformance.
Sign up to view all
COR 12-Month Price Forecast
Cencora presents a balanced risk/reward profile: the forward valuation is attractive, free cash flow is strong, and the specialty business is growing, but thin margins and high leverage limit upside. The stock's low beta and defensive characteristics make it suitable for conservative investors, but the lack of a near-term catalyst and recent underperformance suggest it may remain range-bound. We would upgrade to bullish if gross margins sustainably exceed 4.5% and EPS growth accelerates, or downgrade to bearish if margins fall below 4% or free cash flow deteriorates. The base case (55% probability) sees the stock reaching the analyst average target of $369.25 over 12 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $369.92 and implied upside of +14.2% versus the current price.
Average Target
$369.92
0 analysts
Implied Upside
+14.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$330 - $430
Analyst target range
Cencora is covered by 12 analysts with a consensus recommendation of Buy (recommendation mean of 1.71), and the average target price of $369.25 implies approximately +19.5% upside from the current $309.05 price. The distribution of ratings is skewed bullish, with recent actions from Wells Fargo (Overweight), JP Morgan (Overweight), Morgan Stanley (Overweight), Evercore ISI (Outperform), and UBS (Buy), while RBC Capital and B of A Securities maintain more neutral Sector Perform and Neutral stances. The consensus leans clearly bullish, and the fact that the average target sits above the current price despite the stock's recent 8% monthly decline suggests analysts view the pullback as a buying opportunity rather than a deterioration in fundamentals. The target range spans $330.00 to $430.00, a spread of $100 or roughly 30% of the current price, which signals meaningful disagreement about the company's trajectory. The high target of $430.00 implies roughly +39% upside and likely assumes multiple expansion toward the upper end of the historical range, sustained specialty revenue acceleration, and successful execution on the raised fiscal 2026 EPS guidance. The low target of $330.00 still represents +6.8% upside and likely prices in modest margin compression, slower generic sourcing gains, or a more conservative earnings recovery. The wide spread, combined with the fact that no analyst has a target below the current price, suggests the downside is viewed as limited, but the dispersion indicates uncertainty about the pace of the earnings recovery. Institutional ratings show no recent downgrades — the most recent actions are reiterations of existing ratings — which implies stable sentiment and no negative catalyst in the analyst community, though the lack of upgrades also suggests the bull case is already well understood and priced in.
Bulls vs Bears: COR Investment Factors
The bull case rests on Cencora's specialty-driven revenue growth, robust free cash flow, and a forward PE of 15.59x that appears undemanding for a defensive healthcare distributor with a 0.574 beta. The bear case highlights razor-thin margins (0.90% net), high leverage (D/E of 7.13), and a history of earnings volatility, including a Q4 2025 loss. Currently, the bull evidence is stronger: analysts unanimously see upside (average target $369.25), free cash flow is ample, and the stock trades at a discount to its historical PS multiple. The most critical tension is whether the specialty-driven margin improvement can be sustained; if gross margins hold above 4% and EPS recovery materializes, the stock could re-rate toward the high end of its historical valuation range. Conversely, any margin compression or earnings miss could trigger a sharp de-rating given the already low net margin.
Bullish
- Specialty-driven revenue growth: Q3 2026 revenue grew 5.07% YoY to $84.75 billion, with U.S. Healthcare Solutions contributing $74.86 billion. Management raised FY2026 EPS guidance on the strength of specialty distribution, which is a higher-margin, faster-growing segment than traditional wholesale.
- Strong free cash flow generation: Trailing free cash flow is $4.06 billion, and Q3 2026 alone generated $2.43 billion in FCF on $2.65 billion of operating cash flow. This comfortably funds $1.17 billion in dividends and $1.00 billion in buybacks, supporting shareholder returns.
- Attractive forward valuation: The forward PE of 15.59x is modest for a defensive healthcare distributor, and the PS ratio of 0.19x is well below its historical range of 0.42x–0.78x. This suggests the market is pricing in a normalized earnings recovery that may already be underway.
- Analyst consensus upside: 12 analysts rate the stock a Buy with an average target of $369.25, implying +19.5% upside from $309.05. The low target of $330 still offers +6.8% upside, indicating limited perceived downside.
Bearish
- Razor-thin margins limit cushion: Net margin is just 0.90% and operating margin 1.32%, leaving almost no buffer against pricing or reimbursement shocks. Gross margin of 4.26% is typical for distribution but volatile, having dipped to 3.11% in Q4 2025.
- High leverage and weak liquidity: Debt-to-equity is 7.13 and the current ratio is 0.90, meaning current liabilities exceed current assets. While typical for distributors, this leverage amplifies risk if cash flow deteriorates.
- Recent earnings quality concerns: Q4 2025 posted a net loss of -$339.7 million (EPS -$1.75) due to a -$1.04 billion other-expenses line. Trailing EPS of $0.026 makes the trailing PE of 38.97x meaningless and raises questions about earnings consistency.
- Relative underperformance and weak momentum: The stock has underperformed the S&P 500 by 14.85 percentage points over the past year and by 22.20 percentage points over six months. The 1-month decline of -8.12% versus the S&P's +0.59% shows recent weakness.
COR Technical Analysis
Cencora is in a choppy, range-bound consolidation rather than a clean trend, with a 1-year price change of just +0.16% against a current price of $309.05. That leaves the stock trading at approximately 48.4% of its 52-week range (low of $244.82, high of $377.54), squarely in the middle of its band and suggesting neither momentum-driven overextension nor deep-value capitulation. The -8.80% year-to-date decline and -32.56% max drawdown confirm that the stock has spent most of the past year recovering from a sharp drawdown rather than making new highs, so positioning here is neutral-to-cautious rather than opportunistic. Recent momentum has deteriorated: the 1-month change of -8.12% sharply conflicts with the +4.23% 3-month gain, signaling a fresh pullback within a modest recovery. This divergence is meaningful because the 1-month move has badly lagged the S&P 500's +0.59% over the same period, producing a relative strength of -8.71% for the month, while the 3-month relative strength of +0.89% shows Cencora was keeping pace with the market until very recently. The 6-month change of -4.85% and relative strength of -22.20% indicate the medium-term trend remains one of underperformance, and with a short ratio of 3.82, there is a modest but not extreme bearish positioning that could fuel a squeeze if the stock stabilizes. Key technical levels are defined by the 52-week low at $244.82 as major support and the 52-week high at $377.54 as overhead resistance, with the current $309.05 price sitting roughly $64 above support and $68 below resistance. A breakout above $377.54 would signal a full trend reversal and likely require a fundamental catalyst such as sustained specialty revenue acceleration, while a breakdown below $244.82 would confirm the longer-term downtrend and could open deeper downside. With a beta of just 0.574, Cencora is roughly 43% less volatile than the market, which supports defensive position sizing but also means the stock may lag in strong risk-on rallies; the 1.16 million share volume reading is modest and suggests no urgent institutional accumulation or distribution at current levels.
Beta
0.58
0.58x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
+3.1%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +2.1% |
| 3m | +6.7% | +3.1% |
| 6m | +0.9% | +14.6% |
| 1y | +3.1% | +16.0% |
| ytd | -4.4% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Cencora's revenue trajectory remains solidly growing, with the most recent quarter (ending 2026-06-30) delivering $84.75 billion in revenue and 5.07% year-over-year growth. Sequentially, revenue has been uneven — $85.93 billion in Q1 2026, $78.36 billion in Q2 2026, and $84.75 billion in Q3 2026 — reflecting the seasonal and working-capital-driven lumpiness typical of drug distribution. Segment data shows U.S. Healthcare Solutions generating $74.86 billion, International Healthcare Solutions contributing $7.68 billion, and Other at $2.25 billion, confirming that the domestic specialty and distribution franchise is the overwhelming growth engine. The 5.07% YoY growth rate is respectable for a low-margin distributor and supports the thesis that specialty drug volumes, not price inflation, are driving the top line. Profitability is razor-thin but improving: Q3 2026 net income was $763.5 million on a gross margin of 4.26%, with a net margin of just 0.90% and an operating margin of 1.32%. Gross margin has been volatile — 4.26% in Q3 2026 versus 4.24% in Q2 2026, 3.27% in Q1 2026, and 3.11% in Q4 2025 — but the recent stabilization above 4% is a positive sign for specialty mix and generic sourcing economics. The Q4 2025 net loss of -$339.7 million (EPS of -$1.75) was an outlier driven by a -$1.04 billion other-expenses line, and the return to profitability in subsequent quarters demonstrates the underlying business is sound; however, with a net margin under 1%, Cencora has almost no cushion against pricing or reimbursement shocks. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 7.13 and a current ratio of 0.90, meaning current liabilities exceed current assets — typical for distributors that fund inventory through payables but still a liquidity consideration. Free cash flow is a bright spot at $4.06 billion on a trailing basis, and Q3 2026 alone generated $2.43 billion in FCF on $2.65 billion of operating cash flow, with capital expenditure of just $226 million. ROE of 103.06% is inflated by the very small equity base (a function of the high debt-to-equity ratio) rather than exceptional profitability, so it should be interpreted with caution. The company returned capital via $1.17 billion in dividends and $1.00 billion in buybacks in Q3 2026, funded comfortably by operating cash flow, suggesting the dividend (0.72% yield, 28.1% payout ratio) is secure.
Quarterly Revenue
$84.8B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
4.3%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Because Cencora is profitable — Q3 2026 net income of $763.5 million and trailing EPS of $0.026 — the PE ratio is the appropriate primary metric, though the trailing PE of 38.97x is distorted by the Q4 2025 loss and the very low trailing EPS figure. The forward PE of 15.59x is far more informative and reflects the market's expectation of a sharp earnings recovery, with consensus estimated EPS of $31.74 implying the forward multiple is pricing in normalized profitability. The enormous gap between the trailing PE (38.97x) and forward PE (15.59x) signals that the market expects earnings to more than double, which is consistent with the analyst EPS estimates but leaves little room for disappointment. On a price-to-sales basis, Cencora trades at just 0.19x, and its EV/Sales of 0.213x and EV/EBITDA of 17.91x reflect the low-margin, high-volume nature of distribution. Relative to the broader healthcare distribution sector, the 0.19x PS ratio is in line with the low-single-digit multiples typical of wholesalers, while the 15.59x forward PE sits at a modest premium to the sector's mid-teens average, arguably justified by Cencora's specialty mix and international diversification. The PB ratio of 40.17x is extreme and reflects the tiny book value of equity caused by aggressive leverage and buybacks rather than a genuine valuation premium, so it is not a useful comparison metric here. Historically, Cencora's PE has ranged from roughly 9x to 39x over the past several years, with the current trailing 38.97x near the top of that band — but this is an artifact of depressed trailing earnings, not a genuine re-rating. The more relevant historical comparison is the PS ratio: at 0.19x today versus historical readings of 0.42x to 0.78x over the past three years, the stock is trading at a significant discount to its own sales multiple history, which could signal either a value opportunity or a market that has permanently de-rated the distribution business. The PEG ratio of 7.05 is elevated and suggests the stock is not cheap relative to its growth rate, reinforcing that the forward PE is the more reliable anchor for valuation.
PE
39.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple
Investment Risk Disclosure
Cencora's financial risks are dominated by its razor-thin profitability and high leverage. With a net margin of just 0.90% and operating margin of 1.32%, the company has minimal cushion against drug pricing pressure or reimbursement changes. The debt-to-equity ratio of 7.13 and current ratio of 0.90 indicate that current liabilities exceed current assets, a liquidity profile that, while typical for distributors, leaves little room for error if cash flow slows. Additionally, the Q4 2025 net loss of -$339.7 million (EPS -$1.75) due to a -$1.04 billion other-expenses charge highlights earnings volatility and the potential for one-time items to severely impact results.
Market and competitive risks include the potential for valuation compression if the earnings recovery disappoints. The forward PE of 15.59x assumes EPS of $31.74, a sharp rebound from trailing EPS of $0.026; any shortfall could lead to multiple contraction. The stock's beta of 0.574 provides some insulation from market swings, but its 1-year relative underperformance of -14.85% versus the S&P 500 suggests persistent investor skepticism. Competitive threats from McKesson and Cardinal Health, which together with Cencora control over 90% of the U.S. wholesale market, mean that any loss of market share or pricing pressure from manufacturers could erode margins. Recent news of Cardinal Health's generics profit engine (8-11% growth) underscores the competitive dynamics in the sector.
In a worst-case scenario, a combination of margin compression, slower specialty growth, and a broad market downturn could drive the stock toward its 52-week low of $244.82, representing a decline of approximately 20.8% from the current price of $309.05. If analyst bear-case targets are met, the low target of $330 actually implies upside, but that assumes no deterioration; a more severe scenario could see the stock break below $244.82 if earnings fail to recover. The maximum drawdown over the past year was -32.56%, indicating that investors could lose over 30% from peak levels in adverse conditions. Given the high leverage and thin margins, a recession or significant drug pricing reform could exacerbate the downside, potentially pushing the stock below $250.
FAQ
The key risks include: 1) Financial risk: razor-thin net margin of 0.90% and high debt-to-equity of 7.13 leave little cushion for adverse events; 2) Operational risk: dependence on specialty drug distribution, which could be disrupted by pricing reforms or competition; 3) Market risk: low beta (0.574) reduces volatility but the stock has underperformed the S&P 500 by 14.85% over the past year, and a broader market downturn could pressure the shares; 4) Company-specific risk: earnings volatility, as evidenced by the Q4 2025 net loss of -$339.7 million. The most severe risk is a margin compression scenario that could drive the stock to its 52-week low of $244.82, a 20.8% decline.
Our 12-month forecast has three scenarios: bull case (25% probability) targets $377.54–$430, assuming successful specialty growth and margin expansion; base case (55% probability) targets $330–$369.25, assuming consensus EPS of $31.74 is met; bear case (20% probability) targets $244.82–$300, assuming margin compression and earnings miss. The base case is most likely, with the stock reaching the analyst average target of $369.25, implying 19.5% upside. The key assumption is that gross margins stabilize above 4.2% and revenue grows at 4-6%. If margins fall below 4%, the bear case becomes more probable.
Cencora appears undervalued on a price-to-sales basis, trading at 0.19x versus its historical range of 0.42x–0.78x, but the forward PE of 15.59x is only modestly below the sector average. The trailing PE of 38.97x is distorted by a Q4 2025 loss and low trailing EPS, so the forward PE is more relevant. The PEG ratio of 7.05 suggests the stock is not cheap relative to its growth rate. The market is pricing in an earnings recovery to $31.74 per share, which is a significant increase from trailing EPS of $0.026. If the recovery materializes, the stock could re-rate higher; if not, it may remain range-bound. Relative to peers like McKesson and Cardinal Health, Cencora's valuation is in line, but its specialty mix and international diversification justify a slight premium.
Cencora is a good buy for conservative investors seeking a defensive healthcare stock with a secure dividend and low volatility, but it may not appeal to those seeking high growth. The stock trades at $309.05, with a forward PE of 15.59x and a PS ratio of 0.19x, which is below its historical average. Analysts have a Buy consensus with an average target of $369.25, implying 19.5% upside. However, the company's net margin of 0.90% and high debt-to-equity of 7.13 pose risks. The biggest downside risk is a retest of the 52-week low of $244.82, a 20.8% decline. Overall, it is a reasonable buy for income and stability, but position sizing should account for margin and leverage risks.
Cencora is more suitable for long-term investment due to its defensive characteristics, low beta (0.574), and stable dividend (0.72% yield). The company operates in a mature, oligopolistic industry with steady demand, making it a good candidate for a buy-and-hold strategy. Short-term trading is less attractive given the stock's recent choppy performance and lack of near-term catalysts. A minimum holding period of 2-3 years is recommended to allow the earnings recovery and specialty growth to materialize. The stock's 1-year price change of +0.16% and max drawdown of -32.56% highlight the importance of a long-term perspective to ride out volatility.